Video

Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?

Author(s):

Loretta J. Nastoupil, MD,Marc S. Hoffmann, MD

Experts discuss data on a novel form of CAR T-cell therapy, rapcabtagene autoleucel, for the second-line treatment of R/R LBCL with a faster manufacturing process.

Related Videos
Priya U. Kumthekar, MD
David Schiff, MD
Timothy Gershon, MD, PhD
Jordan Hansford, MD
J. Bradley Elder, MD
Rimas V. Lukas, MD
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Minoo Battiwalla, MD, MS
Paolo Caimi, MD
Related Content
November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Elias Jabbour, MD
November 26th 2024

Obe-Cel Stands Out in ALL as the Sole FDA-Approved CAR T-Cell Therapy Given Via Split Dosing

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Mirdametinib in Adult and Pediatric NF1-PN | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
November 25th 2024

Mirdametinib Improves HRQOL in Adult and Pediatric Patients With NF1-PN

Larotrectinib in TRK Fusion+ CNS Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 24th 2024

Larotrectinib Induces Rapid, Durable Responses in Pediatric Patients With TRK Fusion+ CNS Tumors